Holen Sie sich die Stockscreener-App
2.25
9.27%
-0.23
Handel nachbörslich:
2.39
0.14
+6.22%
Schlusskurs vom Vortag:
$2.48
Offen:
$2.445
24-Stunden-Volumen:
79,677
Relative Volume:
1.86
Marktkapitalisierung:
$2.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-0.1618
EPS:
-13.91
Netto-Cashflow:
$-13.75M
1W Leistung:
-9.64%
1M Leistung:
-23.73%
6M Leistung:
-56.14%
1J Leistung:
-69.14%
1-Tages-Spanne:
$2.25
$2.445
1-Wochen-Bereich:
$2.25
$2.62
52-Wochen-Spanne:
$2.20
$9.25
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(818) 422-6172
Adresse
2110 NARCISSUS CT, VENICE
Vergleichen Sie KTTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
2.25 | 2.86M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 37.2% in December - Defense World
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - GlobeNewswire
Pasithea Therapeutics Corp. Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - Marketscreener.com
KTTA stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $2.33 amid market challenges By Investing.com - Investing.com South Africa
Pasithea Therapeutics Expands Phase 1 Cancer Trial to Europe, Advances PAS-004 Testing - StockTitan
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) and MusclePharm (OTCMKTS:MSLP) - Defense World
KTTA stock touches 52-week low at $2.72 amid market challenges - Investing.com Nigeria
KTTA stock touches 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $2.87 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - The Manila Times
Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan
Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% – Still a Buy? - Defense World
KTTA stock touches 52-week low at $3.19 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $3.19 amid market challenges - Investing.com UK
ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeuti - GuruFocus.com
KTTA stock touches 52-week low at $3.4 amid market challenges - Investing.com Australia
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA) - The Wall Street Transcript
KTTA stock touches 52-week low at $3.6 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $3.6 amid market challenges By Investing.com - Investing.com South Africa
pasithea therapeutics corp Earnings dates - RTTNews
(KTTA) Investment Analysis - Stock Traders Daily
Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com
Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News
PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal
Pasithea Therapeutics drops 19% on $5M private placement - MSN
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal
Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks
Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR
Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices
Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire
Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga
Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance
Why XPeng Stock Spiked Higher Today - Yahoo! Voices
Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL
KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News
Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga
English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices
Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch
Pasithea reports positive early data on cancer drug PAS-004 - Investing.com India
Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):